Sugi Predict

Sugi Predict / Compounds / SCHEMBL544003

SCHEMBL544003

SCHEMBL544003

Cc1ccc(NC(=O)N(S)Cc2ccccc2)cc1Nc1ncc(-c2ccncc2)o1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ KIT P10721 5/20 0.43
▸ KDR P35968 5/20 0.41
▸ FLT1 P17948 4/20 0.41
▸ FLT4 P35916 4/20 0.41
▸ IMPDH2 P12268 1/20 0.41
▸ VCP P55072 1/20 0.39
▸ ABL1 P00519 2/20 0.38
▸ EGFR P00533 1/20 0.38
▸ PDGFRB P09619 1/20 0.38
▸ BCR P11274 1/20 0.38
▸ PDGFRA P16234 1/20 0.38
▸ PRKCA P17252 1/20 0.38
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ ROCK1 Q13464 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL544002 0.80 LSS (0.47) KITKDRFLT1FLT4IMPDH2
SCHEMBL544406 0.79 IMPDH2 (0.62) KITKDRFLT1FLT4IMPDH2
SCHEMBL543758 0.79 PSEN1 (0.51) KITKDRFLT1FLT4ROCK1
SCHEMBL13380736 0.79 KIT (0.43) KITKDRFLT1FLT4IMPDH2
SCHEMBL5712006 0.79 ROCK2 (0.48) KITKDRFLT1FLT4IMPDH2
SCHEMBL544717 0.78 FLT1 (0.42) KITKDRFLT1FLT4IMPDH2
SCHEMBL544184 0.78 KIT (0.46) KITKDRFLT1FLT4IMPDH2
SCHEMBL5712004 0.78 SMN1; SMN2 (0.51) KITMEN1KMT2ASMN1; SMN2
SCHEMBL2343197 0.78 ALDH1A1 (0.47) KITKDRFLT1FLT4IMPDH2
SCHEMBL543650 0.77 ALDH1A1 (0.42) KITKDRFLT1FLT4IMPDH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7718676-B2 E.g., Methyl 4-{[4-Methyl-3-(4-pyridin-3-yl-oxazol-2-ylamino)-phenylamino]-methyl}-benzoate; stem cell factor, bcr-abl, fibroblastic growth factor receptor-3 and Flt-3 inhibitors; treating rheumatoid arthritis, conjunctivitis, rheumatoid spondylitis, osteoarthritis, gouty arthritis, transplant rejection AB SCIENCE (FR) 2010-05-18 — — US claimed
EP-1684750-B1 2-AMINOARYLOXAZOLE COMPOUNDS AS TYROSINE KINASE INHIBITORS AB SCIENCE (FR) 2010-04-28 — — EP claimed
US-20070142390-A1 2-Aminoaryloxazole compounds as tyrosine kinase inhibitors AB SCIENCE 2007-06-21 — — US claimed
EP-1684750-A2 2-AMINOARYLOXAZOLE COMPOUNDS AS TYROSINE KINASE INHIBITORS AB Science (FR) 2006-08-02 — — EP claimed
WO-2005040139-A2 2-AMINOARYLOXAZOLE COMPOUNDS AS TYROSINE KINASE INHIBITORS AB SCIENCE (FR) 2005-05-06 — — WO claimed
US-8110591-B2 2-aminoaryloxazole compounds as tyrosine kinase inhibitors AB SCIENCE (FR) 2012-02-07 — — US disclosed
US-7718676-B2 E.g., Methyl 4-{[4-Methyl-3-(4-pyridin-3-yl-oxazol-2-ylamino)-phenylamino]-methyl}-benzoate; stem cell factor, bcr-abl, fibroblastic growth factor receptor-3 and Flt-3 inhibitors; treating rheumatoid arthritis, conjunctivitis, rheumatoid spondylitis, osteoarthritis, gouty arthritis, transplant rejection AB SCIENCE (FR) 2010-05-18 — — US disclosed
US-20100113471-A1 2-Aminoaryloxazole compounds as tyrosine kinase inhibitors AB SCIENCE 2010-05-06 — — US disclosed
EP-1684750-B1 2-AMINOARYLOXAZOLE COMPOUNDS AS TYROSINE KINASE INHIBITORS AB SCIENCE (FR) 2010-04-28 — — EP disclosed
US-20080146585-A1 Use Of C-Kit Inhibitors For Treating Inflammatory Muscle Disorders Including Myositis And Muscular Dystrophy AB SCIENCE 2008-06-19 — — US disclosed
US-20070249628-A1 Use of Mast Cells Inhibitors for Treating Patients Exposed to Chemical or Biological Weapons MOUSSY ALAIN 2007-10-25 — — US disclosed
US-20070225293-A1 Use of C-Kit Inhibitors for Treating Fibrosis AB SCIENCE 2007-09-27 — — US disclosed
US-20070142390-A1 2-Aminoaryloxazole compounds as tyrosine kinase inhibitors AB SCIENCE 2007-06-21 — — US disclosed
EP-1684750-A2 2-AMINOARYLOXAZOLE COMPOUNDS AS TYROSINE KINASE INHIBITORS AB Science (FR) 2006-08-02 — — EP disclosed
WO-2005040139-A2 2-AMINOARYLOXAZOLE COMPOUNDS AS TYROSINE KINASE INHIBITORS AB SCIENCE (FR) 2005-05-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146585-A1 Use Of C-Kit Inhibitors For Treating Inflammatory Muscle Disorders Including Myositis And Muscular Dystrophy KIT, CPA3, CMA1 KIT 1/4885KDR 1409/4885FLT1 1427/4885
US-20070225293-A1 Use of C-Kit Inhibitors for Treating Fibrosis KIT, CPA3, CMA1 KIT 1/4885KDR 1125/4885FLT1 791/4885
US-20070142390-A1 2-Aminoaryloxazole compounds as tyrosine kinase inhibitors FGFR3, ABL1, FLT3 KIT 9/4885KDR 37/4885FLT1 17/4885
US-20070249628-A1 Use of Mast Cells Inhibitors for Treating Patients Exposed to Chemical or Biological Weapons KIT, CPA3, CMA1 KIT 1/4885KDR 2332/4885FLT1 1829/4885
US-20100113471-A1 2-Aminoaryloxazole compounds as tyrosine kinase inhibitors FGFR3, FLT3, ABL1 KIT 20/4885KDR 41/4885FLT1 25/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.